Stocks to Watch: Gemini Explorations, Inc. (OTCBB: GXPI), Resolve Staffing, Inc. (OTCBB:RSFF) , ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) , Australian-Canadian Oil Royalties Ltd. (OTC BB:AUCAF) , Teeka Tan Products, Inc (OTCBB: TKAT)
Featured Stock: Gemini Explorations, Inc.
(OTCBB: GXPI)
Current Price (0.09)
SmallCap Sentinel: Golden Opportunities
IRVINE, Calif., October 4, 2007 - "With gold up over 22% over the last year alone, heads are starting to turn again in the small cap market,'' stated SmallCap Sentinel analyst D.R. Clark. “Microcap and small cap investors, always eager to ride a wave, are starting to seriously consider gold based public companies. Meanwhile, astute gold bugs are looking for the growth markets within this growth market.”
The informational report ``Investing in Gold Stocks for the SmallCap Investor'' has been made available free of charge at www.SmallCapSentinel.com and will address the rise of interest in gold related equities such as Placer Dome (AMEX:PDG), NovaGold Resources (AMEX:NG), Tao Minerals, Ltd. (OTCBB:TAOL) and Gemini Explorations, Inc. (OTCBB:GXPI)
“One of those potential growth areas may well be Columbia where Gemini Explorations, Inc. (OTCBB:GXPI) is developing two highly prospective gold projects in Colombia including a potential 3.1 million ounce deposit in the Los Andes Sotomayor Gold Belt with a potential asset value of approximately $2 billion at today’s gold prices,” Clark noted from a published report. “Capitalizing on smart acquisitions, modern production techniques, deep industry expertise and the strong bull market for gold, Gemini Explorations is looking to quickly to achieve production, growth and value for shareholders.”
Two investor reports have been made available at the following links. Access to the information is free of charge:
and…
To have your company featured in SmallCap Sentinel please use the contact info below.
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect results. SmallCapSentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
Information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy or offer to sell securities but is rather a paid advertisement provided for information purposes only and shouldn’t be used as the basis for investment decisions. MP is not an investment advisor and this report is not investment advice. MP has been paid $1,500 by Equity Alliance International (www.equityallianceir.com) on behalf of Gemini for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP’s ability to remain objective in communication regarding subject companies.
SmallCap Sentinel and its parent company Market Pathways do not independently verify or guarantee the veracity of any information linked-to from this report. Please contact the aforementioned entities directly for more information about their services and content.
Contact:
Kurt Divich, Editor
Market Pathways/StockUpTicks
702-396-1000
For an in-depth analyst report, please visit: www.WallstreetStockReview.com
Resolve Staffing, Inc.
(OTCBB:RSFF)
Current Price (0.32)
www.WallstreetStockReview.com
ZIOPHARM Oncology, Inc.
(Nasdaq:ZIOP)
Current Price (3.35)
www.WallstreetStockReview.com
NEW YORK--Oct 3--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP - News) announced today that Dr. Barbara Wallner, Senior Vice President, Technical Operations and Chief Technology Officer, will present at the BIO Investor Forum on Wednesday, October 10, 2007 at 10:45 a.m. PT (1:45 ET) at the Palace Hotel in San Francisco, CA. Dr. Wallner will provide an overview of the Company and an update on its clinical development programs. ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. For more information, visit www.ziopharm.com.
Australian-Canadian Oil Royalties Ltd.
(OTC BB:AUCAF)
Current Price (0.40)
www.WallstreetStockReview.com
CISCO,
Teeka Tan Products, Inc
(OTCBB: TKAT)
Current Price (0.03)
www.WallstreetStockReview.com
BOCA RATON, Fla.--Oct 3--Teeka Tan Products, Inc. (OTCBB:TKAT - News) today updated the progress of the proposed merger between Teeka Tan Products (Teeka Tan) and the Taiyuan Rongan Business Trading Company ("TRBT"). On
WallStreetStockReview.com is owned and operated by Iron Consulting.
Verify all claims and do your own due diligence. Iron Consulting profiles are not a solicitation or recommendation to buy, sell or hold securities. Iron Consulting is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Iron Consulting is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b),WallStreetStockReview.com is owned and operated by Iron Consulting. Iron Consulting www.ironconsultinginc.com has receive seventy two thousand dollars in 2006 and thirty six thousand in 2007 from Equity Alliance Intl. www.equityallianceir.com for a internet marketing program. Neither Iron Consulting nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Iron Consulting receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Iron Consulting statements and opinions and such statements and opinions cannot be considered independent. Iron Consulting and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements ar e made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Iron Consulting services are often paid for using free-trading shares. Iron Consulting may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.